After Hours Gainer
NGNE Neurogene19.68-0.41-2.0%
After Hours:24.50+4.82 (+24.5%)
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
Business WireThu, 26-Feb 4:01 PM
After Hours Gainer
NGNE Neurogene19.68-0.41-2.0%
After Hours:25.83+6.15 (+31.3%)
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
Business WireThu, 26-Feb 4:01 PM
NGNE Neurogene20.42-14.09 (-40.8%)
Premarket Decliner
NGNE Neurogene34.51-4.69-12.0%
Premarket:28.50-6.01 (-17.4%)
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
Business WireMon, 18-Nov 6:45 AM
